Hoskuld, just a quick response. The exec's to buy some nominal shares is to show confidence to us the retail holders. Nothing more nothing less. The "new exec" as I suggest would be president. Someone who could take Missling's place if they decide to go it alone and he wants to retire. Someone who Wall St. respects. If the company got bought out then this new President could run the new division for the big pharma. As it relates to the "no definitive rev foundation in place yet" , what pre rev bio has that? But many if not all with the data we have presented had their day in the sun and a huge run up. We haven't. Why? Maybe the answer is in your answer. Trial design issues, bullshit guidance, etc. MAA is our only hope right now. If we get hung up on the first stop for some strange reason we are in for some trouble. I doubt that would happen with all the data out there now but nothing surprises me with Dr. M. The thing that worries me the most is getting approval and then the street say but what about the revenue, lets see that first and they just kick the can down the road. I'm not too worried about that but that would be the Anavex way. In the back of my mind I still think it is because the company did not go public the old fashion way and are being punished. They did the same thing to DNDN back in the day. I am still long and strong and have not sold a dime. Just added along the way. Thanks for the response.
Bullish
Market Data 
Markets 
AI
